Epidemic
ongoing viral pandemic in Nagaland
The COVID-19 pandemic reached the state of Nagaland on 22 May 2020, with its first case confirmed on 25 May 2020.
Officially, Nagaland is the last of the northeastern states after Sikkim to report COVID-19 positive cases.
Fetching the article from Wikipedia…
Text from the Wikipedia article “2020 COVID-19 pandemic in Nagaland”, available under CC BY-SA 4.0.
The COVID-19 pandemic reached the state of Nagaland on 22 May 2020, with its first case confirmed on 25 May 2020. Officially, Nagaland is the last of the northeastern states after Sikkim to report COVID-19 positive cases.
On 22 April, a 33-year-old trader based in Dimapur had tested positive in Gauhati Medical College and Hospital (GMCH).
The man had been admitted to a private hospital in Dimapur for treatment but the hospital referred him to the GMCH as the State did not have testing facilities at that point of time. He tested positive hours after he was shifted in an ambulance.
On 20 July, total number of cases in Nagaland crossed 1000 mark.
Total confirmed cases Active Cases Recoveries Deaths
Covishield
On January 1, 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca's COVID-19 vaccine AZD1222 (marketed as Covishield). Covishield is developed by the University of Oxford and its spin-out company, Vaccitech. It's a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees. It can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf life of at least six months.
Covaxin
On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage.
Text from the Wikipedia article “COVID-19 pandemic in Nagaland”, available under CC BY-SA 4.0.